Sizable investments. High-profile appearances at industry events. Unique development platforms. These elements would augur well for companies of any kind—and companies hoping to bring epigenome ...
The FDA's Peter Marks, M.D., Ph.D., thinks gene editing—specifically base editing—could be a "game changer," but progress has been slow, likely due to discouragement with the regulatory process. Marks ...
A team of physicians and laboratory scientists has taken a key step toward a cure for sickle cell disease, using CRISPR-Cas9 gene editing to fix the mutated gene responsible for the disease in stem ...
Base editors are a type of gene editing tool designed to make precise changes to DNA at the single-nucleotide level. They are used to correct genetic variants that cause disease. 1 This article ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback